Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy

被引：8
|
作者：
von Eyben, Finn Edler [1 ]
Kulkarni, Harshad R. [2 ]
Baum, Richard P. [2 ]
机构：
[1] Ctr Tobacco Control Res, Odense, Denmark
[2] Zentralklin Bad Berka, Theranost Ctr Mol Radiotherapy & Mol Imaging, Bad Berka, Germany
来源：
THERANOSTICS | 2020年 / 10卷 / 11期
关键词：
prostate specific membrane antigen; (177)Lutetium [Lu-177]-PSMA radioligand therapy; prostatic neoplasms; restaging; overall survival;
D O I：
10.7150/thno.44568
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
PSMA based radioligand is a new investigational drug for treatment of metastatic multidrug-resistant and castration-resistant prostate cancer. Prognostic factors point to above and below average overall survival (OS) after the treatment. Kessel et al. [Theranostics 2019;9:4841-8] reported for the first time that two sites of visceral metastases, lungs and liver, differed in impact on OS after treatment with Lu-177 PSMA 617. Treatment with established drugs showed the same trend. The difference in OS between the sites is independent of the type of treatment and can reflect changes in tumor biology during the progression of metastatic prostate cancer.
引用
收藏
页码：4900 / 4902
页数：3
相关论文
共 50 条
  • [21] 177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
    Zang, Jie
    Liu, Qingxing
    Sui, Huimin
    Wang, Rongxi
    Jacobson, Orit
    Zhu, Zhaohui
    Chen, Xiaoyuan
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [22] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
  • [23] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
  • [24] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [25] Comparative Analysis of 177Lu-PSMA Radioligand Therapy Efficacy in Metastatic Castration-Resistant Prostate Cancer: Impact of Taxane Chemotherapy Precedence
    Nazar, A.
    Srivastava, D.
    Ora, M.
    Barai, S.
    Gambhir, S.
    Pradhan, P.
    Arya, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S672 - S672
  • [26] Extended radioligand therapy with Lu-177-PSMA-617 in patients with advanced metastatic castration-resistant prostate cancer
    Mader, N.
    Baumgarten, J.
    Groener, D.
    Ngoc, C. Nguyen
    Davis, K.
    Banek, S.
    Tselis, N.
    Happel, C.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S489 - S489
  • [27] Advances in 177Lu-PSMA and 225Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
    Ling, Sui Wai
    de Blois, Erik
    Hooijman, Eline
    van der Veldt, Astrid
    Brabander, Tessa
    PHARMACEUTICS, 2022, 14 (10)
  • [28] Genetic analysis of metastatic castration resistant prostate cancer patients treated with Lu-177 PSMA radioligand therapy
    Yilmaz, Burcak
    Chalker, Cameron
    Yu, Yun
    Kaempf, Andy
    Mittra, Erik
    Mallak, Nadine
    Sokolova, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Care Pathway at a Cancer Center for the Administration of Radiometabolic Therapy with 177Lu-PSMA in Patients with Metastatic Castration-resistant Prostate Cancer
    Avila, Carlos
    Cadavid, Tatiana
    Martinez, Maria Cristina
    Varela, Humberto
    Hernandez-Hidalgo, Nathalie
    MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, 2024, 33 (01) : 28 - 37
  • [30] Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [177Lu]Lu-PSMA-617 radioligand therapy
    Ahmadzadehfar, Hojjat
    Schlolaut, Stephan
    Fimmers, Rolf
    Yordanova, Anna
    Hirzebruch, Stefan
    Schlenkhoff, Carl
    Gaertner, Florian C.
    Awang, Zool Hilmi
    Hauser, Stefan
    Essler, Markus
    ONCOTARGET, 2017, 8 (61) : 103108 - 103116
12345